PHOSPHORYLATED C-ERBB2 AS A SUPERIOR PREDICTIVE THERANOSTIC MARKER FOR THE DIAGNOSIS AND TREATMENT OF CANCER
摘要
<p>The present invention provides reliable methods to identify subsets of subjects with a cancer of epithelial origin characterized by a high level of phosphorylated c-erbB2 which does not correlate with the over-expression of total c-erbB2 as measured by IHC or FISH, for selection and inclusion for c-erbB2-direct treatment and therapy. Furthermore, the present invention provides a reliable method to determine whether a subject with a cancer of epithelial origin who has been determined to be c-erbB2 positive by IHC and by FISH should be excluded from c-erbB2-direct treatment because of a non-significant level of phosphorylated c-erbB2 in epithelial tumor tissue.</p>
申请公布号
CA2729796(A1)
申请公布日期
2010.01.14
申请号
CA20092729796
申请日期
2009.07.08
申请人
GEORGE MASON INTELLECTUAL PROPERTIES, INC.
发明人
PETRICOIN, EMANUEL, III;LIOTTA, LANCE;ESPINA, VIRGINIA;WULFKUHLE, JULIA